Altria announces Dr. Ellen Strahlman to its Board of Directors

– USA, VA –  Altria Group, Inc. (NYSE: MO) today announces the appointment of Dr. Ellen Strahlman to its Board of Directors effective on November 2, 2020, and will join the Finance and Innovation Committees.

About Dr. Ellen Strahlman

Dr. Strahlman served as EVP, Research & Development and Chief Medical Officer of Becton, Dickinson and Company, a leading global medical technology company, from April 2013 until her retirement in January 2018. Before joining Becton Dickinson and Company, she served as a Senior Advisor to the CEO at GlaxoSmithKline from April 2012 through March 2013, after previously serving as the SVP and Chief Medical Officer from April 2008 through March 2012. Before 2008, Dr. Strahlman held senior executive leadership roles in global product development and commercialization, medical affairs, and business development at leading pharmaceutical and medical technology companies including Pfizer, Inc., Novartis AG, Virogen Limited, Bausch & Lomb, Inc. and Merck & Co., Inc.

She currently serves as a director of Syncona Limited having previously served as a director of Syncona Partners, LLC.

About Altria

Altria’s wholly-owned subsidiaries include Philip Morris USA Inc. (PM USA), U.S. Smokeless Tobacco Company LLC (USSTC), John Middleton Co. (Middleton), Ste. Michelle Wine Estates Ltd. (Ste. Michelle) and Philip Morris Capital Corporation (PMCC). Altria owns an 80% interest in Helix Innovations LLC (Helix). Altria holds equity investments in Anheuser-Busch InBev SA/NV (ABI), JUUL Labs, Inc. (JUUL), and Cronos Group Inc. (Cronos).

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.